Pyxis Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PYXS Nasdaq 2834 www.pyxisoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pyxis Oncology, Inc.

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 30th, 2025 2:30 pm
Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14 - Jun 19th, 2025 5:08 am
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - May 15th, 2025 5:00 am
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - May 14th, 2025 5:30 am
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - Apr 25th, 2025 11:17 am
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Apr 2nd, 2025 5:30 am
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - Mar 25th, 2025 2:30 pm
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 18th, 2025 5:30 am
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - Mar 3rd, 2025 5:30 am
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Feb 26th, 2025 5:30 am
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Feb 23rd, 2025 5:53 am
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Feb 4th, 2025 5:30 am
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Dec 21st, 2024 5:40 am
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - Dec 19th, 2024 2:08 pm
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Dec 1st, 2024 5:06 am
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Nov 27th, 2024 6:16 am
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Nov 20th, 2024 2:05 pm
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 - Nov 12th, 2024 5:30 am
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 - Nov 11th, 2024 5:00 am
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 - Aug 14th, 2024 2:05 pm